Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Express Pharma
CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India
Fitusiran is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents aged 12 years and older, with or without factor VIII or IX inhibitors The post CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India appeared first on Express Pharma.
Read Full Article
Express Pharma
Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing
The partnership will cover technology transfer, clinical manufacturing and commercial production of VeGen Bio’s VL-2511 in India The post Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing appeared first on Express Pharma.
Read Full Article
Pharma Tech
AbbVie races into F1 as pharma companies continue push into sport
AbbVie is just one of several pharmaceutical companies to pen sponsorship deals in sport, blurring the commercial line between the two industries.
Read Full Article
Express Pharma
Exclusive Interview with Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International
On the sidelines of the Bengaluru Pharma Summit, Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International, speaks with Neha Aathavale, Correspondent, Express Pharma […] The post Exclusive Interview with Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International appeared first on Express Pharma.
Read Full Article
Pharma Tech
Pharma’s supplier sprawl problem: When more vendors create less control
Consolidating complicated supply chains with trusted providers reduces governance, sharpens cost and emissions insight, and creates a more resilient, coordinated network.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Oct 22, 2026, 6:26 AM
Zydus recalls anti-inflammatory drug in US after impurity test failure
According to the US FDA latest enforcement report, Zydus has recalled 70776 vials , manufactured at the company’s Vadodara-based facility in India.
ET Pharma
Oct 22, 2026, 5:55 AM
How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Sandoz, in written evidence to British lawmakers earlier this year, said Kundl's capacity to supply Europe was "not commercially sustainable" unless governments paid more for penicillin. It argued that Beijing's control of the penicillin supply chain creates an "inherent strategic risk" akin to China's stranglehold on critical minerals.
PharmaShots
Oct 22, 2026, 5:30 AM
Novartis Receives the EC’s Approval for Cosentyx (Secukinumab) to Treat Polymyalgia Rheumatica (PMR)
Shots: Novartis has received the EC’s approval for Cosentyx (secukinumab) to treat adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or who experience relapse during glucocorticoid taper, making it the 1st & only IL-17A inhibitor approved in Europe for adults with PMR Approval was based on the global P-III (REPLENISH)… The post Novartis Receives the EC’s Approval for Cosentyx (Secukinumab) to Treat Polymyalgia Rheumatica (PMR) appeared first on PharmaShots.
PharmaShots
Oct 22, 2026, 4:30 AM
EQT Private Equity to Acquire QIAGEN for ~$12.1B via All-Cash Public Takeover Offer
Shots: Ref: Business Wire | Image: QIAGEN | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post EQT Private Equity to Acquire QIAGEN for ~$12.1B via All-Cash Public Takeover Offer appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 6:30 PM
AstraZeneca’s Ultomiris (Ravulizumab) Receives the US FDA’s Accelerated Approval to Reduce Proteinuria in Adults with IgA Nephropathy (IgAN)
Shots: Alexion, AstraZeneca Rare Disease has received the US FDA’s accelerated approval for Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression, following Priority Review; it is the 1st & only C5 complement inhibitor approved for this use & marks the 5th indication for Ultomiris Approval… The post AstraZeneca’s Ultomiris (Ravulizumab) Receives the US FDA’s Accelerated Approval to Reduce Proteinuria in Adults with IgA Nephropathy (IgAN) appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 12:25 PM
EMA Marketing Authorization of New Drugs in September 2026
Shots: NewAmsterdam and Menarini Report the EC Approval for Ubeslo and Evlarco for Primary Hypercholesterolemia Company: NewAmsterdam and Menarini Product: Ubeslo and Evlarco Active Ingredient: Obicetrapib and Obicetrapib + Ezetimibe FDC Disease: Primary Hypercholesterolemia Date: Sep 21, 2026 Shots: Editor’s Take: Beyond the Headlines The EC approvals of Ubeslo and Evlarco give NewAmsterdam and Menarini… The post EMA Marketing Authorization of New Drugs in September 2026 appeared first on PharmaShots.
News
Latest industry coverage
Google News
Oct 22, 2026, 7:20 AM
Korea's Samsung Bioepis enters into landmark 10-Year agreement to supply Eculizumab to Brazil - BioSpectrum Asia
Korea's Samsung Bioepis enters into landmark 10-Year agreement to supply Eculizumab to Brazil BioSpectrum Asia
Google News
Oct 22, 2026, 7:00 AM
12 Questions with Julia Jakl - pharmaphorum
12 Questions with Julia Jakl pharmaphorum
Google News
Oct 22, 2026, 6:51 AM
Biotech Ingredient Market Demonstrates Long-Term Growth Potential At 6.6% CAGR - openPR.com
Biotech Ingredient Market Demonstrates Long-Term Growth Potential At 6.6% CAGR openPR.com
Google News
Oct 22, 2026, 6:28 AM
Senores Pharmaceuticals Reappoints Swapnil Shah as Managing Director - hrtoday.in
Senores Pharmaceuticals Reappoints Swapnil Shah as Managing Director hrtoday.in
Google News
Oct 22, 2026, 6:23 AM
Otsuka hit with 11 marketing code breaches after event organizer blunder - Fierce Pharma
Otsuka hit with 11 marketing code breaches after event organizer blunder Fierce Pharma
Google News
Oct 22, 2026, 6:13 AM
Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization - The Manila Times
Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization The Manila Times
Google News
Oct 22, 2026, 6:08 AM
Lee Ki-chan Denies Pharmacy Act Violation Allegations - 조선일보
Lee Ki-chan Denies Pharmacy Act Violation Allegations 조선일보
Google News
Oct 22, 2026, 5:39 AM
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units - WSJ
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units WSJ
Google News
Oct 22, 2026, 4:46 AM
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 - BioSpace
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 BioSpace
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer